Navigation Links
Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that the company's partner, Vical Incorporated, presented positive interim safety and tolerability data on 18 subjects from an ongoing Phase I clinical trial using Inovio's electroporation technology for intratumoral delivery into melanoma tumors of plasmid DNA (pDNA) encoding interleukin-2 (IL-2). The treatment demonstrated objective tumor responses in treated and untreated lesions. The data were presented at the annual meeting of the American Society of Clinical Oncology (Chicago, June 1-5) by Jon M. Richards, M.D., Ph.D., Lutheran General Hospital Division of Hematology/Oncology. Inovio's DNA delivery systems are designed to enhance the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.

The systemic delivery of high-dose recombinant IL-2 to treat melanoma is limited by significant toxicity. An alternative method for extended dosing of IL-2 that may reduce toxicity is by intratumoral injection (followed by electroporation to facilitate cellular uptake) of a plasmid DNA designed to produce IL-2 in the body. The primary objective of this ongoing Phase I pDNA IL-2/electroporation study is to evaluate the safety and tolerability of the latter approach in stage three and four metastatic melanoma patients. In the first stage of the trial, four treatment groups received escalating doses of 0.5, 1.5, 5 (mg per tumor), and 15 mg (5 mg in each of 3 tumors). In the ongoing second stage, patients are treated with the 15 mg dose.

The interim study results show that no serious adverse events related to the study drug or administration procedure have been reported and the treatment was well tolerated. The majority of related adverse events
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
Post Your Comments:
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... CRT-Fallstudien gefragt. Das Problem dabei ist, ... Informationen mit der Kompetenz zu teilen. ... und deshalb freuen wir uns umso mehr, dass ... gebeten, ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)...  Hanger, Inc. (NYSE: HGR ) announced ... operations for the quarter ended September 30, 2014, on ... conference call to discuss these results is scheduled to ... 2014. Those wishing to participate should call 1-877-662-6095. A ... by dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... 2011 Carbylan BioSurgery, Inc. announced today the completion ... trial to evaluate the safety and effectiveness of two ... in patients with osteoarthritis of the knee.   Hydros ... combination products. "Hydros and Hydros TA are ...
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at ... live webcast of the presentation will be available on the ... . A replay will also be available within 24 hours ...
Cached Medicine Technology:Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued 2Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued 3
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
(Date:10/20/2014)... October 20, 2014 Punzoné , the ... the U.S., has a lot to celebrate this month. October ... recognizes the achievements and contributions of Americans of Italian heritage ... Punzoné, and today it shares its favorite Italian cocktails and ... to Italy - even if it is only in a ...
(Date:10/19/2014)... 20, 2014 Recently, BambooIndustry.com, one of ... its new range of bamboo deckings . Moreover, ... natural items; they are now available at deeply discounted ... it is hard to overstate the significance of online ... to online services. The company’s workers are striving to ...
(Date:10/19/2014)... Fancyflyingfox.com, an innovative company that provides many kinds of ... of 2014 mother of the bride dresses . ... with big discounts, up to 70% off. All consumers ... this special offer. , Owing to the company’s ... of the leading brands in the global market. A ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... ... Open in Late 2008, BETHESDA, Md., Feb. 19 Fox ... Living, Inc. (NYSE: SRZ ), continues to thrive during one ... already,been reserved to date and construction on the community is at ...
... revolution taking place,and it,s changing the face of cold-beverage ... that,s more sophisticated than traditional,sodas. Many are looking for ... past, finding a healthy and delicious bottled,drink was no ... are,definitely something to get excited about., "The beverage ...
... CHARLOTTE, N.C., Feb. 19 MedCath Corporation,(Nasdaq: ... has entered into,a new strategic relationship with Solaris ... LLC, will participate in a new venture to ... hospitals, JFK,Medical Center and Muhlenberg Regional Medical Center. ...
... 19 With Presidential,candidates campaigning -- and smiling ... Michael Kosdon has had ample opportunity to,judge their ... has,picked a winner., "I would definitely say ... than Hillary Clinton," says Kosdon, who has,transformed hundreds ...
... Inc., the worldwide leader,in handheld X-ray technologies, today ... available. The NOMAD Pro builds upon,the heritage of ... http://www.newscom.com/cgi-bin/prnh/20080219/LATU057 ), "The NOMAD has forever changed ... an operator to safely stay in the room ...
... medication, error prevention outreach and education for HIMSS attendees wearing custom ... ... BRUNO, Calif., Feb. 19 First DataBank, a leading,provider of drug ... to focus public and industry attention on the,prevention of medication errors. ...
Cached Medicine News:Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 2Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 3Health News:Fox Hill Senior Condominium Development Thrives During National Housing Slump 4Health News:The Search for Healthier Drinks Turns Up Yerba Mate 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 2Health News:MedCath Announces Venture With Two New Jersey Hospitals 3Health News:Smiling on the Campaign Trail - Cosmetic Dentist Michael Kosdon Rates the Candidates 2Health News:Aribex Unveils New Handheld Intraoral X-ray System - NOMAD Pro 2Health News:First DataBank Launches Campaign to Focus Public and Industry Attention on Medication Error Prevention 2Health News:First DataBank Launches Campaign to Focus Public and Industry Attention on Medication Error Prevention 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: